Payment overview · 2025
General Payments
$1,938.32
16 reported records · 10 companies
Healthcare provider profile · identity verified
Armando Onel Martinez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MERRITT ISLAND, FL · NPI 1043305949
Verified facts
What the public records show
CMS Open Payments records show Armando Onel Martinez, M.D. received $1,938.32 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $559.85 | 28.9% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $299.72 | 15.5% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $245.11 | 12.7% | 2 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $149.86 | 7.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $125.00 | 6.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $125.00 | 6.5% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $125.00 | 6.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.46 | 6.4% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $93.66 | 4.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $90.66 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,938.32 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $299.72 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $299.72 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $245.11 | 2 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $149.86 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Biological | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $93.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $93.36 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $90.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 711 | 534 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 550 | 55 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 436 | 435 |
| Oxycodone Hcl | Oxycodone Hcl | 313 | 29 |
| Alprazolam | Alprazolam | 304 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 268 | 30 |
| Lorazepam | Lorazepam | 253 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 44 |
| Potassium Chloride | Potassium Chloride | 154 | 39 |
| Lisinopril | Lisinopril | 150 | 43 |
| Tramadol Hcl | Tramadol Hcl | 147 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 144 | 44 |
| Furosemide | Furosemide | 143 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 139 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 25 |
| Clonazepam | Clonazepam | 119 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 21 |
| Gabapentin | Gabapentin | 116 | 26 |
| Atorvastatin Calcium | Atorvastatin Calcium | 107 | 34 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 103 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 21 |
| Omeprazole | Omeprazole | 88 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 88 | 20 |
| Metformin Hcl | Metformin Hcl | 87 | 23 |
| Temazepam | Temazepam | 84 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 75 | 75 |
| Eliquis | Apixaban | 74 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 20 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 69 | 69 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 28 |
| Carvedilol | Carvedilol | 62 | 18 |
| Simvastatin | Simvastatin | 61 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 59 | 18 |
| Losartan Potassium | Losartan Potassium | 58 | 16 |
| Ozempic | Semaglutide | 57 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 13 |
| Clonidine Hcl | Clonidine Hcl | 51 | 11 |
| Prednisone | Prednisone | 49 | 23 |
| Pregabalin | Pregabalin | 49 | 11 |
| Meclizine Hcl | Meclizine Hcl | 48 | 17 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 47 | suppressed |
| Meloxicam | Meloxicam | 47 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 12 |
| Montelukast Sodium | Montelukast Sodium | 44 | 11 |
| Allopurinol | Allopurinol | 43 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Desloratadine | Desloratadine | 37 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 12 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Tadalafil | Tadalafil | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,938.32 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BESREMI, BREZTRI, CARVYKTI, DATROWAY, Kerendia, Korlym, LIBTAYO, Nubeqa, OPDIVO, PROVENGE, RYBREVANT, SARCLISA, ZEPZELCA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error